Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the transaction, the chief executive officer directly owned 1,599,154 shares in the company, valued at approximately $57,201,738.58. This represents a 11.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00.
• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $34.18 on Thursday. Roivant Sciences Ltd. has a one year low of $12.28 and a one year high of $37.97. The firm’s 50 day simple moving average is $35.27 and its two-hundred day simple moving average is $31.09. The stock has a market capitalization of $24.69 billion, a P/E ratio of -64.49 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. As a group, equities analysts expect that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on ROIV. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and an average target price of $35.14.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp increased its position in shares of Roivant Sciences by 8.7% in the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock valued at $130,000 after acquiring an additional 376 shares during the period. Bessemer Group Inc. raised its stake in shares of Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after acquiring an additional 441 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its holdings in shares of Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after purchasing an additional 445 shares during the period. Versant Capital Management Inc boosted its holdings in shares of Roivant Sciences by 13.9% during the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock worth $141,000 after purchasing an additional 487 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its stake in shares of Roivant Sciences by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.